Skip to content
Baret News – Lifestyle
Author:
Rezolute, Inc.
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
June 17, 2026
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
June 4, 2026
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
June 2, 2026
←
Previous Page
1
2